Senti Biosciences, Inc.
SNTI
$2.10
$0.041.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 10.52M | 10.03M | 9.28M | 7.77M | 8.66M |
| Gross Profit | -10.52M | -10.03M | -9.28M | -7.77M | -8.66M |
| SG&A Expenses | 8.00M | 5.18M | 5.40M | 6.65M | 6.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -178.00K | -- | -- |
| Total Operating Expenses | 18.52M | 15.21M | 14.51M | 14.42M | 14.90M |
| Operating Income | -18.52M | -15.21M | -14.51M | -14.42M | -14.90M |
| Income Before Tax | -18.13M | -14.73M | -14.11M | -610.00K | -28.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.13M | -14.73M | -14.11M | -610.00K | -28.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.13M | -14.73M | -14.11M | -610.00K | -28.87M |
| EBIT | -18.52M | -15.21M | -14.51M | -14.42M | -14.90M |
| EBITDA | -17.61M | -14.30M | -13.58M | -13.49M | -13.96M |
| EPS Basic | -0.69 | -0.56 | -1.41 | -1.34 | -6.31 |
| Normalized Basic EPS | -0.43 | -0.35 | -0.88 | -0.17 | -1.52 |
| EPS Diluted | -0.69 | -0.56 | -1.41 | -1.34 | -6.31 |
| Normalized Diluted EPS | -0.43 | -0.35 | -0.88 | -0.17 | -1.52 |
| Average Basic Shares Outstanding | 26.23M | 26.08M | 10.01M | 4.66M | 4.58M |
| Average Diluted Shares Outstanding | 26.23M | 26.08M | 10.01M | 4.66M | 4.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |